Financial conflicts of interest in biomedical research: The need to improve the system

Drug News and Perspectives

Volumn 23, Issue 9, 2010, Pages 607-612

  Wang, Amy T ^a   Montori, Victor M ^a   Murad, Mohammad Hassan ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; FUNDING; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INTERPERSONAL COMMUNICATION; MAMMOTH; MEDICAL RESEARCH; NONHUMAN; PHYSICIAN; PREVALENCE; REVIEW; ARTICLE; COOPERATION; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; INDUSTRY; ORGANIZATION;

ACADEMIES AND INSTITUTES; BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; COOPERATIVE BEHAVIOR; INDUSTRY; RESEARCH SUPPORT AS TOPIC;

EID: 79952278522     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.9.1521763     Document Type: Review

References (56)

1. Fahrenthold, D.A. Report shows close ties between rig inspectors, oil industry. The Washington Post, May 26, 2010. http://www.washingtonpost.com/ wpdyn/content/article/2010/05/25/AR2010052502817.html. Accessed June 12, 2010.
2. Lo, B., Field, M.J. (Eds.). Conflict of Interest in Medical Research, Education, and Practice. The National Academies Press: Washington, D.C. 2009.
3. Cohen, J.J. Trust us to make a difference: ensuring public confidence in the integrity of clinical research. Acad Med 2001, 76(2): 209-14. (Pubitemid 32151890)
4. Levinsky, N.G. Nonfinancial conflicts of interest in research. N Engl J Med 2002, 347(10): 759-61. (Pubitemid 35203910)
5. Relman, A.S. Dealing with conflicts of interest. N Engl J Med 1984, 310(18): 1182-3. (Pubitemid 14135395)
6. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals. http://www.icmje.org/. Accessed October 29, 2010.
7. Moher, D., Schulz, K.F., Altman, D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357(9263): 1191-4. (Pubitemid 32378696)
8. Schulz, K.F., Altman, D.G., Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340: c332.
9. Drazen, J.M., Van der Weyden, M.B., Sahni, P. et al. Uniform format for disclosure of competing interests in ICMJE journals. JAMA 2010, 303(1): 75-6.
10. Schacht, W.H. Congressional Research Service Report for Congress. The Bayh-Dole Act: Selected issues in patent policy and the commercialization of technology. http://assets.opencrs.com/rpts/RL32076-20080403.pdf. Accessed June 15, 2010.
11. Center for the Health Professions at the University of California San Francisco. Trends in U.S. funding for biomedical research. http://www. futurehealth.ucsf.edu/Content/29/1996-12-Trends-in-US-Funding-for-Biomedical- Research.pdf. Accessed June 17, 2010.
12. Dorsey, E.R., de Roulet, J., Thompson, J.P. et al. Funding of US biomedical research, 2003-2008. JAMA 2010, 303(2): 137-43.
13. Gifts to physicians from industry. JAMA 1991, 265(4): 501.
14. Pharmaceutical Research and Manufacturers of America. Code on Interactions with Healthcare Professionals. 2008. http://www.phrma.org/files/ attachments/PhRMA%20Marketing%20Code%202008.pdf. Accessed June 27, 2010.
15. Report to Congressional Requesters United States Government Accountability Office: Prescription Drugs. 2002. http://www.gao.gov/new.items/ d03177.pdf. Accessed June 28, 2010.
16. Report to Congressional Requesters United States Government Accountability Office: Prescription Drugs. 2006. http://www.gao.gov/new.items/ d0754.pdf. Accessed June 28, 2010.
17. More clarity needed in funding of patient groups. Prescrire Int 2010, 19(105): 43.
18. Wilson, P. European drug regulator is criticized over patient representatives' conflicts of interest. BMJ 2010, 340: c3349.
19. Campbell, E.G., Gruen, R.L., Mountford, J., Miller, L.G., Cleary, P.D., Blumenthal, D. A national survey of physician-industry relationships. N Engl J Med 2007, 356(17): 1742-50. (Pubitemid 46658706)
20. Bekelman, J.E., Li, Y., Gross, C.P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003, 289(4): 454-65. (Pubitemid 36119966)
21. Campbell, E.G., Weissman, J.S., Ehringhaus, S., Rao, S.R., Moy, B., Feibelmann, S., Goold, S.D. Institutional academic industry relationships. JAMA 2007, 298(15): 1779-86.
22. Kjaergard, L.L., Als-Nielsen, B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002, 325(7358): 249.
23. Bhandari, M., Busse, J.W., Jackowski, D. et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004, 170(4): 477-80. (Pubitemid 38293642)
24. Als-Nielsen, B., Chen, W., Gluud, C., Kjaergard, L.L. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003, 290(7): 921-8.
25. Ross, J.S., Hill, K.P., Egilman, D.S., Krumholz, H.M. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008, 299(15): 1800-12. (Pubitemid 351549971)
26. Rennie, D. Thyroid storm. JAMA 1997, 277(15): 1238-43.
27. McCarthy, M. Company sought to block paper's publication. Lancet 2000, 356: 1659.
28. Berenson, A. Evidence in Vioxx suits show intervention by Merck officials. The New York Times, April 24, 2005. http://www.nytimes.com/2005/04/ 24/business/24drug.html. Accessed October 29, 2010.
29. Johansen, H.K., Gotzsche, P.C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999, 282(18): 1752-9. (Pubitemid 29533606)
30. Patsopoulos, N.A., Ioannidis, J.P., Analatos, A.A. Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 2006, 332(7549): 1061-4.
31. Wang, A.T., McCoy, C.P., Murad, M.H., Montori, V.M. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ, 340: c1344.
32. Vastag, B. Reviewer leaked Avandia study to drug firm. Nature 2008, 451(7178): 509. (Pubitemid 351186243)
33. Josiah Macy Junior Foundation. Continuing education in the health professions: improving healthcare through lifelong learning. 2008. http://www.josiahmacyfoundation.org/documents/pub-ContEd-inHealthProf.pdf. Accessed June 19, 2010.
34. Bowman, M.A., Pearle, D.L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988, 8(1): 13-20.
35. Chren, M.M., Landefeld, C.S. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994, 271(9): 684-9.
36. Moynihan, R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ 2008, 336(7658): 1402-3.
37. Large pharmaceutical companies tend to pay triple what other size companies do for KOL speakers [news release]. Marketwire, March 19, 2010. http://www.marketwire.com/mw/release.do?id=834122. Accessed June 15, 2010.
38. Taylor, R., Giles, J. Cash interests taint drug advice. Nature 2005, 437(7062): 1070-1. (Pubitemid 41509317)
39. Brennan, T.A., Rothman, D.J., Blank, L. et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006, 295(4): 429-33. (Pubitemid 43144979)
40. Lurie, N., Rich, E.C., Simpson, D.E., Meyer, J., Schiedermayer, D.L., Goodman, J.L., McKinney, W.P. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med 1990, 5(3): 240-3. (Pubitemid 20175498)
41. Bower, A.D., Burkett, G.L. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract 1987, 24(6): 612-6. (Pubitemid 17107966)
42. Cain, D.M., Loewenstein, G. The dirt on coming clean: perverse effects of disclosing Conflicts of Interest. J Legal Studies 2005, 34(1): 1-25. (Pubitemid 40549835)
43. DeAngelis, C.D., Fontanarosa, P.B., Flanagin, A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA 2001, 286(1): 89-91. (Pubitemid 32606337)
44. Okike, K., Kocher, M.S., Wei, E.X., Mehlman, C.T., Bhandari, M. Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med 2009, 361(15): 1466-74.
45. Harvard Medical School Dean accepts recommendations for revising conflicts of interest policy [news release]. Harvard Medical School, July 21, 2010. http://hms.harvard.edu/public/coi/newsroom/2010/july-news-release.html. Accessed August 9, 2010.
46. Begg, C., Cho, M., Eastwood, S. et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 276(8): 637-9. (Pubitemid 26278070)
47. Kaiser, J. National Institutes of Health. Lowering the boom on financial conflicts. Science, 328(5982): 1091.
48. Rockey, S.J., Collins, F.S. Managing financial conflict of interest in biomedical research. JAMA, 303(23): 2400-2.
49. Kuehn, B.M. Payments to physicians, medical schools to be illuminated under new reform law. JAMA, 303(22): 2237-8.
50. Singer, N. Stanford Medical School to expand ethics rules. The New York Times, March 21, 2010. http://www.nytimes.com/2010/03/22/health/policy/22docs. html. Accessed October 29, 2010.
51. Martin, J.B. The pervasive influence of conflicts of interest: a personal perspective. Neurology, 74(24): 2016-21.
52. Wilson, D. Using a Pfizer grant, courses aim to avoid bias. The New York Times, January 11, 2010. http://www.nytimes.com/2010/01/11/business/11drug.html. Accessed October 29, 2010.
53. Kile, A., Johnson, S. OREF finds new ways to partner with industry. AAOS Now, September, 2009. http://www.aaos.org/news/aaosnow/sep09/research1.asp. Accessed October 29, 2010.
54. OREF 2010-2011 CDP funding pool is $7.5 million. AAOS Now, March, 2010. Accessed October 29, 2010.
55. Morris, L., Taitsman, J.K. The agenda for continuing medical education - limiting industry's influence. N Engl J Med 2009, 361(25): 2478-82.
56. Kruytbosch, C.E. Academic-corporate research relationships: forms, functions, and fantasies. J Dent Res 1982, 61(6): 729-33.